By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ascenta Therapeutics Inc. 

11455 El Camino Real, Suite 460

San Diego  California  92130  U.S.A.
Phone: 858-436-1200 Fax: 858-436-1201


SEARCH JOBS








Company News
Debiopharm and Ascenta Therapeutics Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various Tumors 9/7/2011 6:03:26 AM
Ascenta Therapeutics Inc. and The Leukemia & Lymphoma Society Announce Agreement to Develop AT-406 for Leukemia 12/6/2010 11:58:07 AM
Sanofi-Aventis (France) (SASY.PA), Ascenta Therapeutics Inc. Agree Up To $398 Mln Cancer R&D Deal 6/4/2010 7:48:18 AM
Ascenta Therapeutics Inc. Announces Presentation of Results From a Dose-Ranging Study of AT-101 With Standard Therapy in Patients With Glioblastoma Multiforme 10/26/2009 8:48:43 AM
Ascenta Therapeutics Inc. Receives Clearance to Initiate Clinical Trials With AT-406 9/10/2009 7:56:53 AM
Ascenta Therapeutics Inc. Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 American Society of Clinical Oncology Annual Meeting 6/1/2009 8:48:10 AM
Ascenta Therapeutics Inc. Announces Multiple Presentations on AT-101 at 2009 American Society of Clinical Oncology Annual Meeting 5/26/2009 9:01:46 AM
Ascenta Therapeutics Inc. Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models 4/21/2009 8:55:27 AM
Ascenta Therapeutics Inc. Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer 2/27/2009 9:59:57 AM
Ascenta Therapeutics Inc. Highlights Multiple Data Presentations at This Week's AACR-NCI-EORTC International Conference in San Francisco 10/24/2007 9:56:26 AM
12
//-->